**Supplementary Table 1. Descriptions of prognostic risk models for PBC**

|  |  |  |
| --- | --- | --- |
|  | **Time of Evaluation** | **Definition of suboptimal treatment response** |
| **Rotterdam**  | 1 year | Abnormal bilirubin and/or albumin |
| **Paris I** | 1 year | ALP ≥ 3 x ULN or AST ≥ 2 x ULN or bilirubin > 1 mg/dl |
| **Paris II** | 1 year | ALP > 1.5 x ULN or AST > 1.5 x ULN or bilirubin > 1 mg/dl  |
| **Barcelona** | 1 year | ALP > 1 x ULN and decrease in ALP < 40% |
| **Toronto** | 2 years | ALP > 1.67 x ULN |
|  | **Time of Evaluation** | **Calculation** |
| **APRI** | Baseline | AST/ULN of AST/platelet (x 109) x 100 |
| **APRI-r1** | 1 year | AST/ULN of AST/platelet (x 109) x 100 |

PBC, primary biliary cholangitis; ALP, alkaline phosphatase; ULN, upper limit of normal; APRI, AST to platelet ratio index; APRI-r1, APRI at 1-year; AST, aspartate aminotransferase; ALT, alanine aminotransferase